Published in Korean J Radiol on June 21, 2010
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology (2014) 1.33
APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol (2011) 1.24
ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol (2015) 1.03
Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol (2011) 0.94
New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer (2012) 0.92
Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One (2013) 0.88
MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid. Korean J Radiol (2013) 0.84
Multiparametric MR Imaging in Abdominal Malignancies. Magn Reson Imaging Clin N Am (2016) 0.83
Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. Int J Hepatol (2011) 0.80
Imaging of HCC-Current State of the Art. Diagnostics (Basel) (2015) 0.79
Detection of recurrent hepatocellular carcinoma in cirrhotic liver after transcatheter arterial chemoembolization: value of quantitative color mapping of the arterial enhancement fraction of the liver. Korean J Radiol (2012) 0.78
Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T. Acta Radiol Open (2015) 0.75
A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology (1983) 30.77
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology (2005) 2.50
Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology (1995) 2.38
Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol (2009) 2.23
Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. Radiology (2004) 2.05
Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol (2009) 1.89
Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology (1992) 1.65
Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol (2004) 1.56
Susceptibility artefacts in NMR imaging. Magn Reson Imaging (1985) 1.54
Coil sensitivity encoding in MR imaging: advantages and disadvantages in clinical practice. AJR Am J Roentgenol (2002) 1.53
Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol (2010) 1.44
Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther (1999) 1.44
Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology (1996) 1.42
Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol (1998) 1.31
On comparisons of sensitivity, specificity and predictive value of a number of diagnostic procedures. Biometrics (1972) 1.31
Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol (2009) 1.17
Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol (1999) 1.17
Hepatocellular carcinoma: are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation? Radiology (2000) 1.06
Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol (1998) 1.05
Paired receiver operating characteristic curves and the effect of history on radiographic interpretation. CT of the head as a case study. Radiology (1983) 1.00
The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol (2008) 0.92
Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol (2006) 0.92
Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology (2003) 0.92
Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol (2004) 0.91
Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol (1993) 0.90
High field body MR imaging: preliminary experiences. Clin Imaging (2004) 0.88
Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol (2009) 0.87
Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol (2006) 0.84
Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging (1993) 0.82
Diagnosis of small hepatocellular carcinoma. Hepatology (2005) 0.80
Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J Immunol (2004) 3.27
Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology (2012) 2.36
Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics (2003) 2.24
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95
Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol (2009) 1.89
Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment. Ann Surg (2010) 1.84
Sequential activation of phosphatidylinositol 3-kinase, beta Pix, Rac1, and Nox1 in growth factor-induced production of H2O2. Mol Cell Biol (2004) 1.82
Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. AJR Am J Roentgenol (2005) 1.79
Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol (2006) 1.79
Endovascular treatment of wide-necked aneurysms by using two microcatheters: techniques and outcomes in 25 patients. AJNR Am J Neuroradiol (2005) 1.63
Review of failed CT phantom image evaluations in 2005 and 2006 by the CT accreditation program of the Korean Institute for Accreditation of Medical Image. Korean J Radiol (2008) 1.60
Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol (2005) 1.57
Endovascular treatment of blood blister-like aneurysms of the internal carotid artery. J Neurosurg (2007) 1.55
Evaluation of esophageal varices on liver computed tomography: receiver operating characteristic analyses of the performance of radiologists and endoscopists. J Gastroenterol Hepatol (2009) 1.53
Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med (2009) 1.51
Developing an institutional protocol guideline for laparoscopy-assisted distal gastrectomy. Ann Surg Oncol (2009) 1.51
Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol (2012) 1.47
The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol (2010) 1.45
Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog (2002) 1.43
Changes in the signal- and contrast-to-noise ratios of hepatocellular carcinomas on gadoxetic acid-enhanced dynamic MR imaging. Eur J Radiol (2012) 1.42
Technical feasibility and safety of laparoscopy-assisted total gastrectomy in gastric cancer: a comparative study with laparoscopy-assisted distal gastrectomy. J Surg Oncol (2009) 1.41
Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.38
Primary Budd-Chiari syndrome: outcome of endovascular management for suprahepatic venous obstruction. J Vasc Surg (2006) 1.36
Intraductal papillary mucinous tumor of the bile ducts. Radiographics (2004) 1.34
Diffusion-weighted magnetic resonance imaging for the evaluation of prostate cancer: optimal B value at 3T. Korean J Radiol (2012) 1.33
Hepatic hemangioma: atypical appearances on CT, MR imaging, and sonography. AJR Am J Roentgenol (2003) 1.29
Ascending retrocecal appendicitis: clinical and computed tomographic findings. J Comput Assist Tomogr (2006) 1.26
Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: initial experience. AJR Am J Roentgenol (2008) 1.22
"Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol (2009) 1.22
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci (2010) 1.21
Needle tract implantation after percutaneous interventional procedures in hepatocellular carcinomas: lessons learned from a 10-year experience. Korean J Radiol (2008) 1.20
Hepatic visceral larva migrans of Toxocara canis: CT and sonographic findings. AJR Am J Roentgenol (2006) 1.19
Coagulation necrosis induced by radiofrequency ablation in the liver: histopathologic and radiologic review of usual to extremely rare changes. Radiographics (2011) 1.17
Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol (2008) 1.17
Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol (2009) 1.16
Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults. Eur J Nucl Med Mol Imaging (2008) 1.15
Neuroendocrine neoplasms of the gastrointestinal tract: classification, pathologic basis, and imaging features. Radiographics (2007) 1.15
The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol (2010) 1.15
Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology (2012) 1.14
Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol (2007) 1.14
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer Res Treat (2012) 1.14
Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdom Imaging (2009) 1.13
Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol (2011) 1.13
Differential diagnosis for intrahepatic biliary cystadenoma and hepatic simple cyst: significance of cystic fluid analysis and radiologic findings. J Clin Gastroenterol (2010) 1.12
Glomus tumor of the stomach: a clinicopathologic analysis of 10 cases and review of the literature. Gut Liver (2012) 1.12
Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonography. AJR Am J Roentgenol (2012) 1.11
Utilization of the emergency room: impact of geographic distance. Geospat Health (2007) 1.11
The specific role of pRb in p16 (INK4A) -mediated arrest of normal and malignant human breast cells. Cell Cycle (2012) 1.10
Radiological findings of spinal schwannomas and meningiomas: focus on discrimination of two disease entities. Eur Radiol (2009) 1.09
Vitamin D inadequacy is associated with significant coronary artery stenosis in a community-based elderly cohort: the Korean Longitudinal Study on Health and Aging. J Clin Endocrinol Metab (2011) 1.09
Lung adenocarcinoma as a solitary pulmonary nodule: prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer (2009) 1.08
Spectrum of CT findings after radiofrequency ablation of hepatic tumors. Radiographics (2008) 1.07
Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT. AJR Am J Roentgenol (2005) 1.06
Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity. Am J Clin Oncol (2010) 1.06
Therapeutic efficacy and safety of percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the gastrointestinal tract. AJR Am J Roentgenol (2004) 1.05
Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics (2003) 1.05
Percutaneous radiofrequency ablation for the hepatocellular carcinoma abutting the diaphragm: assessment of safety and therapeutic efficacy. Korean J Radiol (2009) 1.05
Small submucosal tumors of the stomach: differentiation of gastric schwannoma from gastrointestinal stromal tumor with CT. Korean J Radiol (2012) 1.04
Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging. Eur J Radiol (2005) 1.04